The board of directors of Sino Biopharmaceutical Limited announced that CP Pharmaceutical (Qingdao) Co., Ltd., a subsidiary of the Company, entered into an exclusive commercial cooperation agreement with Shandong Boan Biotechnology Co., Ltd. (Boan Biotech), pursuant to which, CP Qingdao has been granted the exclusive commercialisation rights for Denosumab Injection (Boyoubei®) in Mainland China by Boan Biotech. The authorization period under the agreement is five years, after the expiry of which CP Qingdao shall have the priority to renew the commercialization authorization of this product on the same conditions. Boyoubei® can form a competitive product portfolio with CP Qingdao's existing products in this field to create greater synergy.

With its professional commercialization and extensive clinical endpoint coverage team in the field of osteoporosis, CP Qingdao will accelerate the commercialization of Boyoubei® to meet the urgent clinical needs of Chinese patients.